Table 4.
Summary of features and results of clinical studies applying adipose-derived SVF and microfragmented adipose tissue for the treatment of knee OA
| References | Cell donor | Patients | Study design | Study results | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients | Knee OA grading | Age range | Type of study (ClinicalTrials.gov Identifier if applies) | Experimental group(s) | Cell dosage | Treatment comparator | Final follow-up | Measurements | Main outcomes | ||
| Pak [39] | Autologous | 2 | N/A | 70–79 years | Case series | Injection of SVF combined with PRP and dexamethasone, followed by weekly PRP injections for 1 month | N/A | – | 3 months |
VAS Knee motion range Functional rating index MRI |
↓ Pain ↑ Knee function Note: no statistical analysis on average data available |
| Gibbs [40] | Autologous | 4 | N/A | 23–50 years | Case series | Injection of SVF combined with PRP followed by monthly PRP injections for 4 months | 11.5 × 106 − 50 × 106 cells | – | 12 months |
Knee injury and OA outcome score Physical function test |
↓ Pain ↑ Knee function Note: no statistical analysis on average data available |
| Pak [41] | Autologous | 3 | KL III | 60–87 years | Case series | Injection of SVF combined with HA + PRP followed by weekly HA + PRP injections for 3 weeks | N/A | – | 5 months |
VAS Knee motion range Functional rating index MRI |
↓ Pain ↑ Knee function Note: no statistical analysis on average data available |
| Fodor [42] | Autologous | 6 (8 knees) | KL I–III | 51–69 years |
Phase I open-label single-arm clinical trial (NCT02357485) |
Injection of SVF | 14.1 × 106 cells | – | 12 months |
VAS WOMAC OA index Knee motion range MRI |
↓ Pain ↑ Knee function Improvements at 3 months maintained at 12 months |
| Bansal [43] | Autologous | 10 (13 knees) | KL I–II | ≥ 50 years |
Phase I open-label single-arm clinical trial (NCT03089762) |
Injection of SVF combined with PRP | N/A | – | 24 months |
WOMAC OA index 6-min walk distance MRI |
↓ Pain ↑ Knee function ↑ Walking distance Improvements maintained at 24 months |
| Hudetz [44] | Autologous | 17 (32 knees) | KL II–IV | 40–85 years | Prospective, open-label single-arm, clinical trial | Injection of micro-fragmented adipose tissue | N/A | – | 12 months |
VAS X-rays dGEMRIC MRI IgG glycome composition in blood plasma and synovial fluid |
Treatment safety ↓ Pain ↑ Knee function ↑ Glycosaminoglycan content in residual areas of cartilage |